Navigation Links
Quartesian LLC Executes Multi-Year Enterprise Agreement with Medrio, Securing Access to Innovative eClinical Functionality and Support Services
Date:4/17/2019

Quartesian LLC, a full-service contract research organization (CRO) providing data management, biostatistics, and other services to clinical trial sponsors, has entered into a multi-year agreement with Medrio, a leading provider of eClinical technology for clinical trials. The agreement will enable Quartesian, a member of Medrio’s Certified Partner Program, to leverage the full range of Medrio’s products including EDC, eConsent, ePRO, and Direct Data Capture (DDC) to support their clients in the emerging growth biotech and pharma spaces.

“The Medrio system will be a key asset in our efforts to compress timelines, reduce costs, and improve data cleanliness in our clinical trials, enabling us to deliver top-quality services to our clients and free up resources to work more productively,” commented Stephen Boccardo, Senior Vice President of Business Development and Commercial Strategy at Quartesian. “We fully expect our partnership with Medrio over the course of this agreement to be fulfilling and mutually beneficial.”

The agreement also enables Quartesian, as a member of the Medrio Partner Program, to access a wide range of exclusive support services geared toward facilitating new connections between CROs and study sponsors. “We’re excited to announce this multi-year partnership between Quartesian and Medrio,” commented Steve Geffon, Chief Commercial Officer at Medrio. “By leveraging the functionality of Medrio’s eClinical platform and the support services of the Certified Partner Program, we expect Quartesian to be successful in exceeding their corporate objectives.”

About Quartesian LLC
Quartesian LLC was formed in January 2003 and is headquartered in Princeton, N.J. with the goal of providing “Clinical Data Your Way” to its clients. This goal is accomplished by providing clinical data services faster, more efficient and cost-effective than ever thought possible. The founding members of Quartesian rely not only on their technical expertise, but also on their experience as past clients of clinical service providers. Quartesian prides itself on its flexibility, responsiveness, adherence to client specifications and timelines for all projects conducted anywhere in the world. We have worked for over 100+ pharmaceutical, biotechnology and medical device companies with 100% repeat business and no change orders.

About Medrio
Medrio is the leading provider of eClinical technology for early-phase pharma, device, and diagnostics clinical trials. Founded in 2005, the company's cloud-based EDC, eSource, eConsent, and ePRO solutions deliver fast, flexible, and easy-to-use tools for the collection and management of clinical data and patient reported outcome responses. Study sponsors and contract research organizations have used Medrio extensively in clinical trials across a wide array of therapeutic areas, with notable success in oncology, infectious disease, and more. Medrio has extensive experience in all study phases and leads the market in early-phase trials. The company serves over 500 customers globally, with headquarters in San Francisco and offices in numerous domestic and international locations. For more information, please visit medrio.com.

Read the full story at https://www.prweb.com/releases/quartesian_llc_executes_multi_year_enterprise_agreement_with_medrio_securing_access_to_innovative_eclinical_functionality_and_support_services/prweb16248859.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. EyeLock Appoints Michael Fiorito Vice President of Enterprise Accounts
2. Barley business for beer brewing nets scientists enterprise funding
3. EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments
4. Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector
5. HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars
6. Fujitsu Refreshes Mobile and Desktop Portfolio for the Enterprise
7. Mantu to Unveil Highly Secured Enterprise P2P Messaging Platform at MWC 2016
8. Atheer to Bring AiR Suite for Enterprise to Recon Jet Smart Eyewear
9. Scripps Research announces research & license agreement with Janssen Pharmaceuticals
10. Eurofins MWG Operon and Floragenex close co-marketing agreement for RAD discovery and RAD genotyping
11. IDRI and Zydus sign agreement for development of IDRIs vaccine candidate for visceral leishmaniasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2020)... ... July 09, 2020 , ... Today CJ BIO announced ... will share insight on the “fifth taste” phenomenon that is revolutionizing ingredient mixes, nutritional ... Advantage will be live on Monday, July 13, 2020 at11:00 AM (CDT) during SHIFT20, ...
(Date:7/1/2020)... N.J. (PRWEB) , ... July 01, 2020 , ... ... announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in ... the company’s existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot ...
(Date:6/25/2020)... Mass. (PRWEB) , ... June 24, 2020 , ... ... of cloud-based enterprise software and software-driven clinical data services that accelerate drug development, ... for low-dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... ... June 29, 2020 , ... ... procured purchasing contracts to its membership, recently named BioFit Engineered Products ... the opportunity to purchase ergonomic seating, cafeteria tables, book trucks and carts at ...
(Date:6/28/2020)... ... June 26, 2020 , ... The Security Industry Association ... strong opposition to the recently introduced bicameral Facial Recognition and Biometric Technology ... federal use of nearly all biometric and related image analytics technologies, incorrectly labeling ...
(Date:6/23/2020)... Ore. (PRWEB) , ... June 23, 2020 , ... ... of innovative CNS therapies, today announced that it has filed an Investigational New ... a Phase 2b clinical trial of its lead drug candidate NBTX-001 in patients ...
(Date:6/11/2020)... ... 09, 2020 , ... Reducing carbon emissions has been and will continue to ... stock market dips, ways to reduce CO2 is something we can’t avoid. , ... the biofuels being produced today are created from recycled cooking oil or crops. Unfortunately, ...
Breaking Biology Technology: